InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2019 - 2026)

InMed Pharmaceuticals has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $50509.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 3.43% year-over-year to $50509.0; the trailing twelve-month figure through Mar 2026 stood at $209664.0 (down 2.42% YoY), and the FY2025 full-year result was $212839.0, down 3.08% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $50509.0, down from $53201.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $55231.0 in Q4 2023, with the low at $49048.0 in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $52878.1 across 5 years, with a median of $53203.0 in 2024.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 94.52% — and 2023, when it slipped 4.97%.
• InMed Pharmaceuticals' Depreciation & Amortization (CF) stood at $49049.0 in 2022, then grew by 12.6% to $55231.0 in 2023, then retreated by 3.67% to $53203.0 in 2024, then dropped by 0.0% to $53201.0 in 2025, then declined by 5.06% to $50509.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $50509.0 (Q1 2026), $53201.0 (Q4 2025), and $53202.0 (Q3 2025), per Business Quant data.